Sponsored by:

Molecular Imaging

Varian highlights Fast-02 proton Flash therapy trial results
By AuntMinnie.com staff writers
Most participants reported complete pain relief at three months and with no adverse events from treatment.
July 16, 2026
(From left to right) Researchers Emily Daugherty, MD, Anthony Mascia, PhD, and John Perentesis, MD, inside the proton therapy treatment room at the Cincinnati Children's/University of Cincinnati Medical Center Proton Therapy Center.
AdvanCell raises $315M for targeted alpha therapy
By AuntMinnie.com staff writers
The company is developing ADVC001, a lead-212 (Pb-212)-based targeted alpha therapy for metastatic prostate cancer.
July 15, 2026
Cash Bills
Brain PET scans reveal neuron loss in long COVID
By Will Morton
The findings suggest that treatments aimed at boosting dopamine release could be repurposed to treat long COVID.
July 14, 2026
Representative participant from each group shown. C-11 DTBZ non-displaceable binding potential (BPND) in voxels quantitated with simplified reference tissue model 2. Color scale indicates C-11 DTBZ BPND from 0 (black) to 3.5 (red), with reduced C-11 DTBZ BPND observed in the long COVID case compared to both healthy controls.
Nucs AI, Segmed to build AI validation platform for theranostics
By AuntMinnie.com staff writers
The companies will develop disease-specific registries, curated research cohorts, and validation frameworks.
July 14, 2026
Artificial Intelligence Ai 400
Actineer completes Ra-226 recycling process to support Ac-225 supply
By AuntMinnie.com staff writers
This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.
July 14, 2026
Nuclear Medicine Worker Sm
New PET tracer show promise in neuroblastoma
By Will Morton
F-18 mFBG achieved a pooled sensitivity of 97%, compared with 82% for I-123 MIBG.
July 9, 2026
Cancer Target
GE HealthCare, Mayo Clinic begin new theranostics trial in Minnesota
By AuntMinnie.com staff writers
First U.S. site to investigate the StarGuide GX SPECT/CT technology.
July 8, 2026
Atom Nuclear Lab Thumb
Molecular Partners, Orano Med dose first patients in MP0712 trial
By AuntMinnie.com staff writers
MP0712 is a designed ankyrin repeat protein (DARPin) that targets delta-like ligand 3 (DLL3).
July 2, 2026
Nuclear Medicine
PET/MRI can reduce the need for biopsies in prostate cancer
By Will Morton
Prostate biopsies are associated with considerable morbidity, including pain, rectal bleeding, prostatitis, and urinary tract infections.
July 2, 2026
A visual abstract of the study.
Radnostix acquires Lara System, Ellexa software from Lucerno
By AuntMinnie.com staff writers
The acquisitions also include associated intellectual property for monitoring radiopharmaceutical administration.
July 2, 2026
Radiation Therapy Planning 400 (3)
PET/CT guides treatment in men with recurrent prostate cancer
By Will Morton
F-18 fluciclovine and Ga-68 PSMA-11 PET/CT have similar benefits for sRT planning, in terms of improving cancer control without increased toxicity.
June 30, 2026
F-18 fluciclovine PET/CT images in a 59-year-old man with biochemical recurrence after prostatectomy (prostate-specific antigen level, 0.42 ng/mL; Gleason score, 5 + 4 = 9; T3BN1M0). (A) Coronal PET and (B) maximum intensity projection images show multiple retroperitoneal lymph nodes with abnormal radiotracer uptake (arrows). (C) Axial PET and (D) axial fused PET/CT images show the index lesion (arrow), measuring 13 × 10 mm, on the right precaval lymph node. The initial decision to offer radiation therapy to the prostate bed and pelvis was changed to a decision not to offer radiation therapy.
RefleXion Medical submits FDA 510(k) for Anchor Point tumor tracking
By AuntMinnie.com staff writers
RefleXion Medical is seeking FDA clearance for the company's Anchor Point Tracking tech for radiotherapy use.
June 30, 2026
Anchor Point Tracking, designed for use with the new RefleXion X2 platform, underpins SCINTIX therapy with higher fidelity biologic data.
Page 1 of 631
Next Page